Brief: Sight Sciences Receives FDA 510(K) Clearance Of The Tearcare System For Treatment Of Meibomian Gland Dysfunction (Mgd), The Leading Cause Of Dry Eye Disease
22/12/2021 13:13
Dec 22 (Reuters) - Sight Sciences Inc SGHT.O :
* SIGHT SCIENCES RECEIVES FDA 510(K) CLEARANCE OF THE
TEARCARE®
SYSTEM FOR TREATMENT OF MEIBOMIAN GLAND DYSFUNCTION (MGD), THE
LEADING CAUSE OF DRY EYE DISEASE
Source text for Eikon: ID:nGNX90ys6n
Further company coverage: SGHT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sight Sciences
See all newsSight Sciences, Inc. reports results for the quarter ended June 30 - Earnings Summary
Sight Sciences Q2 revenue rises 20%, beats estimates
Brief: Sight Sciences Q2 Revenue USD 23.4 Million Vs. IBES Estimate USD 21.7 Million
Sight Sciences, Inc. expected to post a loss of 15 cents a share - Earnings Preview
Sight Sciences raises FY 2026 revenue outlook